tiprankstipranks
Unity Bio Stock Soars on Promising Phase 2 DME Data
Market News

Unity Bio Stock Soars on Promising Phase 2 DME Data

Shares of biotechnology company Unity Biotechnology (NASDAQ:UBX) are flying high today on promising data from a Phase 2 study evaluating UBX1325 for the treatment of diabetic macular edema (DME).

Impressively, at 24 weeks post a single dose, subjects saw a +7.6 ETDRS letter improvement from baseline.  Further, the injection also showed a favorable safety and tolerability profile.

The company now plans to begin a pivotal study for DME in H2 2023.

Read full Disclosure

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles